Shanghai OPM Biosciences (SH:688293)2024-10-15 08:42Group 1: Investor Relations Activities - The investor relations activity took place on October 11, 2024, at 1:00 PM in the company meeting room [2] - Attendees included representatives from various institutions such as Zheshang Asset Management and Yongying Fund [2] Group 2: Company Strategy and Mergers - The company is actively looking for merger and acquisition opportunities, with a recent investment in Haixing Biotechnology in June 2024, aimed at expanding its biomanufacturing platform [2] - Regulatory policies have been introduced to support mergers and acquisitions, and the company will fulfill its information disclosure obligations as required [2] Group 3: Product Pricing and Sales - The competition for the 293 series products in the domestic market is intense, leading the company to offer discounts based on customer situations [3] - The pricing for CHO series products is flexible and based on a tiered agreement that adjusts according to usage [3] Group 4: Financial Projections and Expenses - The company plans to maintain its expenditure for the U.S. subsidiary in the second half of the year at levels similar to the first half, indicating a gradual investment phase [3] - The overlap of customers between CDMO and culture media segments is acknowledged, suggesting potential synergies [3] Group 5: Shareholder Actions - Recent disclosures indicated that shareholders, including Tianjin Huajie and Shanghai Panxin, have reduced their holdings, but the reductions did not meet the initially planned proportions [3] - The company will assist shareholders in fulfilling their information disclosure obligations regarding any future reduction plans [3]